Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants

This publication has 12 references indexed in Scilit:

• Blood Group, Immunity, and Risk of Infection with Vibrio cholerae in an Area of Endemicity
  Infection and Immunity, 2005
• Randomized, Controlled Study of the Safety and Immunogenicity of Peru‐15, a Live Attenuated Oral Vaccine Candidate for Cholera, in Adult Volunteers in Bangladesh
  The Journal of Infectious Diseases, 2005
• Supplementation with Zinc, but Not Vitamin A, Improves Seroconversion to Vibriocidal Antibody in Children Given an Oral Cholera Vaccine
  The Journal of Infectious Diseases, 2003
• Randomized, Controlled Human Challenge Study of the Safety, Immunogenicity, and Protective Efficacy of a Single Dose of Peru-15, a Live Attenuated Oral Cholera Vaccine
  Infection and Immunity, 2002
• Selection for in vivo regulators of bacterial virulence
  Proceedings of the National Academy of Sciences, 2001
• Evaluation of Peru‐15, a New Live Oral Vaccine for Cholera, in Volunteers
  The Journal of Infectious Diseases, 1997
• Peru-15, an Improved Live Attenuated Oral Vaccine Candidate for Vibrio cholerae O1
  The Journal of Infectious Diseases, 1995
• Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children
  The Lancet, 1992
• Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development.
  Proceedings of the National Academy of Sciences, 1989
• SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD 103 AND CVD 103-HgR
  The Lancet, 1988